This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mund, C. Articles by Lyko, F. Search for Related Content PubMed PubMed Citation Articles by Mund, C. Articles by Lyko, F. Related Collections Clinical Intervention Clinical Intervention: Biomarkers

Characterization of DNA Demethylation Effects Induced by 5-Aza-2'-Deoxycytidine in Patients with Myelodysplastic Syndrome

¹ Research Group Epigenetics, Deutsches Krebsforschungszentrum, Heidelberg and ² Department of Hematology, University of Freiburg Medical Center, Freiburg, Germany

Requests for reprints: Frank Lyko, Research Group Epigenetics, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 580, 69120 Heidelberg, Germany. Phone: 49-6221-42-3800; Fax: 49-6221-42-3802; E-mail: f.lyko{at}dkfz.de.

Azanucleoside drugs such as 5-azacytidine (Vidaza) and 5-aza-2'-deoxycytidine (decitabine, Dacogen) function as DNA methyltransferase inhibitors in vitro and represent promising new drugs for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia. In this study, we aimed to determine the effect of decitabine on the genomic methylation level in MDS patients. Comparison of different assays established micellar electrokinetic chromatography as a reliable method for the analysis of genomic methylation levels. When used for the determination of DNA methylation levels in bone marrow DNA from MDS patients during various time points of decitabine treatment, the results revealed a significant (up to 70%) demethylation in five of seven patients. Interestingly, genome-wide demethylation appeared after karyotype normalization, which suggests demethylation of nonclonal cells. Drug-induced demethylation dynamics were also confirmed by bisulfite sequencing of pericentromeric satellite elements. Our results are the first to show a genome-wide demethylating activity of decitabine in tumor material. In addition, our data uncovers novel targets of decitabine-mediated demethylation that are important for the refinement of treatment schedules with demethylating drugs.

This article has been cited by other articles:

				S. S. Palii, B. O. Van Emburgh, U. T. Sankpal, K. D. Brown, and K. D. Robertson DNA Methylation Inhibitor 5-Aza-2'-Deoxycytidine Induces Reversible Genome-Wide DNA Damage That Is Distinctly Influenced by DNA Methyltransferases 1 and 3B Mol. Cell. Biol., January 15, 2008; 28(2): 752 - 771. [Abstract] [Full Text] [PDF]

				J.-P. J. Issa DNA Methylation as a Therapeutic Target in Cancer Clin. Cancer Res., March 15, 2007; 13(6): 1634 - 1637. [Abstract] [Full Text] [PDF]

				Z. Liu, S. Liu, Z. Xie, W. Blum, D. Perrotti, P. Paschka, R. Klisovic, J. Byrd, K. K. Chan, and G. Marcucci Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method Nucleic Acids Res., March 12, 2007; 35(5): e31 - e31. [Abstract] [Full Text] [PDF]

				S. Agrawal, M. Unterberg, S. Koschmieder, U. zur Stadt, U. Brunnberg, W. Verbeek, T. Buchner, W. E. Berdel, H. Serve, and C. Muller-Tidow DNA Methylation of Tumor Suppressor Genes in Clinical Remission Predicts the Relapse Risk in Acute Myeloid Leukemia Cancer Res., February 1, 2007; 67(3): 1370 - 1377. [Abstract] [Full Text] [PDF]

				S. D. Gore, S. Baylin, E. Sugar, H. Carraway, C. B. Miller, M. Carducci, M. Grever, O. Galm, T. Dauses, J. E. Karp, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res., June 15, 2006; 66(12): 6361 - 6369. [Abstract] [Full Text] [PDF]

				A. S. Yang, K. D. Doshi, S.-W. Choi, J. B. Mason, R. K. Mannari, V. Gharybian, R. Luna, A. Rashid, L. Shen, M. R.H. Estecio, et al. DNA Methylation Changes after 5-Aza-2'-Deoxycytidine Therapy in Patients with Leukemia. Cancer Res., May 15, 2006; 66(10): 5495 - 5503. [Abstract] [Full Text] [PDF]

				F. Lyko and R. Brown DNA Methyltransferase Inhibitors and the Development of Epigenetic Cancer Therapies J Natl Cancer Inst, October 19, 2005; 97(20): 1498 - 1506. [Abstract] [Full Text] [PDF]